Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Hampton, Daniel D ^a   Hale, Laura P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DIPHENHYDRAMINE; HISTAMINE H2 RECEPTOR; PIROXICAM; TUMOR NECROSIS FACTOR; CYCLOOXYGENASE 1; HISTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENZYME INHIBITION; EPITHELIUM CELL; HISTAMINE RELEASE; MAST CELL; MOUSE; NONHUMAN; PEPTIC ULCER; STOMACH ACID SECRETION; STOMACH EPITHELIUM; STOMACH PROTECTION; TISSUE REPAIR; WILD TYPE; 129 MOUSE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STOMACH MUCOSA; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DIPHENHYDRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GASTRIC MUCOSA; HISTAMINE; HUMANS; MAST CELLS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PEPTIC ULCER; PIROXICAM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051630271     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023669     Document Type: Article

References (57)

1. Kumar V, Abbas AK, Fausto N, Aster JC, (2010) Robbins and Cotran Pathologic Basis of Disease, 8th edition Saunders Elsevier, Philadelphia, PA 1450 p.
2. Yuan Y, Padol IT, Hunt RH, (2006) Peptic ulcer disease today. Nat Clin Pract Gastroenterol Hepatol 3: 80-89.
3. Wolfe MM, Lichtenstein DR, Singh G, (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888-1899.
4. Singh G, Triadafilopoulos G, (1999) Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 56: 18-24.
5. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, (1995) Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 40: 1345-1350.
6. Tamblyn R, Berkson L, Dauphinee WD, Gayton D, Grad R, et al. (1997) Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 127: 429-38.
7. Barkun A, Leontiadis G, (2010) Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Amer J Med 358: 366.
8. Sung JJY, Kuipers EJ, El-Serag HB, (2010) Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharm Ther 29: 938-946.
9. Zhu A, Kaunitz J, (2008) Gastric mucosal defense. Curr Gastroenterol Rep 10: 548-554.
10. Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, et al. (1995) The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 30: 289-299.
11. Krumholz HM, (2007) What have we learnt from Vioxx? Brit Med J 334: 120-123.
12. Malhotra S, Shafiq N, Pandhi P, (2004) COX-2 inhibitors: a CLASS act or Just VIGORously promoted. Med Gen Med 6: 6.
13. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 352: 1092-1102.
14. Hsiao FY, Tsai YW, Huang WF, (2009) Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan. Clin Ther 31: 2618-2627.
15. Barozzi N, Tett SE, (2007) What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf 16: 1184-91.
16. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, et al. (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492.
17. Darling RL, Romero JJ, Dial EJ, Akunda JK, Langenbach R, et al. (2004) The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterol 127: 94-104.
18. Djahanguiri B, Abtahi FS, Hemmati M, (1973) Prevention of aspirin-induced gastric ulceration by bile duct or pylorus ligation in the rat. Gastroenterol 65: 630-633.
19. Abtahi FS, Djahanguiri B, (1975) Decreased incidence of indomethacin-induced gastric ulceration in rats by bile duct diversion. Br J Surg 62: 113-4.
20. Berrozpe G, Timokhina I, Yukl S, Tajima Y, Ono M, et al. (1999) The Wsh, W57, and Ph Kit expression mutations define tissue-specific control elements located between -23 and -154 kb upstream of Kit. Blood 94: 2658-2666.
21. Wolters PJ, Clair JM-S, Lewis CC, Villalta SA, Baluk P, et al. (2005) Tissue-selective mast cell reconstitution and differential lung gene expression in mast cell-deficient KitW-sh/KitW-sh sash mice. Clinical & Experimental Allergy 35: 82-88.
22. Echtenacher B, Mannel DN, Hultner L, (1996) Critical protective role of mast cells in a model of acute septic peritonitis. Nature 103: 75-77.
23. Malaviya R, Ikeda T, Ross E, Abraham SN, (1996) Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α. Nature 381: 77-80.
24. McLachlan JB, Hart JP, Pizzo SV, Shelburne CP, Staats HF, et al. (2003) Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nature Immunol 4: 1199-1205.
25. Scheiman JM, Hindley CE, (2010) Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 32: 667-677.
26. Lacy ER, Ito S, (1984) Rapid epithelial restitution of the rat gastric mucosa after ethanol injury. Lab Invest 51: 573-583.
27. Wallace JL, McKnight GW, (1990) The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterol 99: 295-304.
28. Wallace JL, (2008) Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88: 1547-1565.
29. Tarnawski AS, (2005) Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 50: S24-33.
30. Uspenskiľ VM, Grinevich VB, (1980) Mast cells as a criterion of repair process activity in ulcerative stomach lesions. Arkh Patol 42: 14-19.
31. Shimada M, Kitamura Y, Yokoyama M, Miyano Y, Maeyama K, et al. (1980) Spontaneous stomach ulcer in genetically mast-cell depleted W/Wv mice. Nature 283: 662-664.
32. Nakajima S, Arizono N, Hattori T, Bamba T, (1996) Increase in mucosal and connective tissue-type mast cells in the stomach with acetic acid-induced ulcer in rat. APMIS 104: 19-29.
33. Rudzki Z, Stachura J, Dabroś W, Brzozowski T, (1995) The mast cells and an experimental gastric ulcer. Histochemical, ultrastructural and quantitative study in the rat. Pol J Pathol 46: 225-234.
34. Wallace JL, Granger DN, (1996) The cellular and molecular basis of gastric mucosal defense. FASEB J 10: 731-740.
35. Egozi EI, Ferreira AM, Burns AL, Gamelli RL, Dipietro LA, (2003) Mast cells modulate the inflammatory but not the proliferative response in healing wounds. Wound Repair Regen 11: 46-54.
36. Oehmichen M, Gronki T, Meissner C, Anlauf M, Schwark T, (2009) Mast cell reactivity at the margin of human skin wounds: an early cell marker of wound survival? Forensic Sci Int 191: 1-5.
37. Weller K, Foitzik K, Paus R, Syska W, Maurer M, (2006) Mast cells are required for normal healing of skin wounds in mice. FASEB J 20: 2366-2368.
38. Shiota N, Nishikori Y, Kakizoe E, Shimoura K, Niibayashi T, et al. (2010) Pathophysiological role of skin mast cells in wound healing after scald injury: study with mast cell-deficient W/W(V) mice. Int Arch Allergy Immunol 151: 80-88.
39. Jameson J, Havran WL, (2007) Skin gamma delta T-cell functions in homeostasis and wound healing. Immunol Rev 215: 114-122.
40. Azuma T, Dojyo M, Ito S, Yamazaki Y, Miyaji H, et al. (1999) Bile reflux due to disturbed gastric movement is a cause of spontaneous gastric ulcer in W/Wv mice. Dig Dis Sci 44: 1177-83.
41. Hull MA, Cullen DJ, Hudson N, Hawkey CJ, (1995) Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration. Gut 37: 610-612.
42. Hull MA, Knifton A, Filipowicz B, Brough JL, Vautier G, et al. (1997) Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration. Gut 40: 204-210.
43. Basso D, Navaglia F, Brigato L, Di Mario F, Rugge M, et al. (1999) Helicobacter pylori non-cytotoxic genotype enhances mucosal gastrin and mast cell tryptase. J Clin Pathol 52: 210-214.
44. Cairns JA, Walls AF, (1996) Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule-1 expression. J Immunol 156: 275-283.
45. Grosman N, (2007) Comparison of the influence of NSAIDs with different COX-selectivity on histamine release from mast cells isolated from naïve and sensitized rats. Intl Immunopharmacol 7: 532-540.
46. Gomes JC, Pearce FL, (1988) Comparative studies on the effect of nonsteroidal anti-inflammatory drugs (NSAID) on histamine release from mast cells of the rat and guinea pig. Agents Actions 24: 266-71.
47. De Paulis A, Ciccarelli A, Marinò I, De Crescenzo G, Marinò D, et al. (1997) Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. Arthritis Rheum 40: 469-78.
48. Rostom A, Dube C, Wells G, Tugwell P, Welch V, et al. (2002) Prevention of NSAID-induced gastroduodenal ulcers.Cochrane Database Syst Rev pp. CD002296.
49. Ehsanullah RS, Page MC, Tildesley G, Wood JR, (1988) Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. Brit Med J 297: 1017-1021.
50. Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, et al. (2007) Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 11: iii-iv 1-164.
51. Taha AS, McCloskey C, Prasad R, Bezlyak V, (2009) Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374: 119-125.
52. Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, et al. (2007) Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102: 507-515.
53. Ng FH, Lam KF, Wong SY, Chang CM, Lau YK, et al. (2008) Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy. Digestion 77: 173-177.
54. Chichlowski M, Westwood GS, Abraham SN, Hale LP, (2010) Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLOS One 5: e12220.
55. Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earle KA, et al. (2002) Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterol 123: 1527-1542.
56. Hale LP, Gottfried MR, Swidsinski A, (2005) Piroxicam treatment of IL-10 deficient mice enhances colon epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm Bowel Dis 11: 1060-1069.
57. Gompertz RHK, Mant WK, Lit SK, Spencer J, Baron JH, Michalowski AS, (1991) Acid blockade by omeprazole or ICI 162846 in a chronic duodenal ulcer model. Agents & Action 33: 161-163.